These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 30003313)
1. Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis. Pratt RD; Grimberg S; Zaritsky JJ; Warady BA Pediatr Nephrol; 2018 Nov; 33(11):2151-2159. PubMed ID: 30003313 [TBL] [Abstract][Full Text] [Related]
2. Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Fishbane SN; Singh AK; Cournoyer SH; Jindal KK; Fanti P; Guss CD; Lin VH; Pratt RD; Gupta A Nephrol Dial Transplant; 2015 Dec; 30(12):2019-26. PubMed ID: 26175145 [TBL] [Abstract][Full Text] [Related]
3. Ferric pyrophosphate citrate for parenteral administration of maintenance iron: structure, mechanism of action, clinical efficacy and safety. Fishbane S; Ganz T; Pratt RD Curr Med Res Opin; 2022 Aug; 38(8):1417-1429. PubMed ID: 35726771 [TBL] [Abstract][Full Text] [Related]
4. Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Gupta A; Lin V; Guss C; Pratt R; Ikizler TA; Besarab A Kidney Int; 2015 Nov; 88(5):1187-94. PubMed ID: 26154926 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate. Marbury T; van Heuveln F; van der Horst E; Pratt RD J Clin Pharmacol; 2022 May; 62(5):681-688. PubMed ID: 34743348 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers. Pratt RD; Swinkels DW; Ikizler TA; Gupta A J Clin Pharmacol; 2017 Mar; 57(3):312-320. PubMed ID: 27557937 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease. Gan L; Xie P; Tan Y; Wei G; Yuan X; Lu Z; Pratt R; Zhou Y; Hui AM; Li K; Fang Y; Zuo L Drugs R D; 2022 Jun; 22(2):119-129. PubMed ID: 35380419 [TBL] [Abstract][Full Text] [Related]
8. Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis. Shah HH; Hazzan AD; Fishbane S Semin Nephrol; 2016 Mar; 36(2):124-9. PubMed ID: 27236134 [TBL] [Abstract][Full Text] [Related]
9. Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis. Zhang L; Gan L; Li K; Xie P; Tan Y; Wei G; Yuan X; Pratt R; Zhou Y; Hui AM; Fang Y; Zuo L; Zheng Q Eur J Clin Pharmacol; 2022 Sep; 78(9):1421-1434. PubMed ID: 35711066 [TBL] [Abstract][Full Text] [Related]
10. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Gupta A; Amin NB; Besarab A; Vogel SE; Divine GW; Yee J; Anandan JV Kidney Int; 1999 May; 55(5):1891-8. PubMed ID: 10231452 [TBL] [Abstract][Full Text] [Related]
11. Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis. Fishbane S; Shah HH Hemodial Int; 2017 Jun; 21 Suppl 1():S104-S109. PubMed ID: 28371161 [TBL] [Abstract][Full Text] [Related]
12. New Options for Iron Supplementation in Maintenance Hemodialysis Patients. Vaziri ND; Kalantar-Zadeh K; Wish JB Am J Kidney Dis; 2016 Mar; 67(3):367-75. PubMed ID: 26616335 [TBL] [Abstract][Full Text] [Related]
13. A Review of Ferric Pyrophosphate Citrate (Triferic) Use in Hemodialysis Patients. Albright T; Al-Makki A; Kalakeche R; Shepler B Clin Ther; 2016 Oct; 38(10):2318-2323. PubMed ID: 27692637 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing. Diebold M; Kistler AD BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916 [TBL] [Abstract][Full Text] [Related]
15. Triferic for iron replacement. Med Lett Drugs Ther; 2017 Mar; 59(1517):55-56. PubMed ID: 28323812 [No Abstract] [Full Text] [Related]
16. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial. Goldstein SL; Morris D; Warady BA Am J Kidney Dis; 2013 Apr; 61(4):588-97. PubMed ID: 23245582 [TBL] [Abstract][Full Text] [Related]
17. Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. Macdougall IC; White C; Anker SD; Bhandari S; Farrington K; Kalra PA; McMurray JJV; Murray H; Steenkamp R; Tomson CRV; Wheeler DC; Winearls CG; Ford I; Am J Nephrol; 2018; 48(4):260-268. PubMed ID: 30304714 [TBL] [Abstract][Full Text] [Related]
18. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial . Macdougall IC; Strauss WE; Dahl NV; Bernard K; Li Z Clin Nephrol; 2019 Apr; 91(4):237-245. PubMed ID: 30802204 [TBL] [Abstract][Full Text] [Related]
19. Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis. Drozdz M; Weigert A; Silva F; Frazão J; Alsuwaida A; Krishnan M; Kleophas W; Brzosko S; Johansson FK; Jacobson SH BMC Nephrol; 2019 Jan; 20(1):5. PubMed ID: 30616548 [TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Schiller B; Bhat P; Sharma A Clin Ther; 2014 Jan; 36(1):70-83. PubMed ID: 24315802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]